52 Week Range
As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Lundbeck Completes Acquisition Of Alder Biopharmaceuticals
Lundbeck And Takeda Announce Trintellix Approval In Japan
Alder Biopharma Says If Co Terminates Lundbeck Deal To Enter Into A Superior Proposal, Co Will Be Required To Pay Termination Fee Of $87 Mln
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Biotechnology & Drugs
Lars Soeren Rasmussen
Independent Chairman of the Board
Deborah L. Dunsire
President, Chief Executive Officer, Interim Executive Vice President Research & Development
Deputy Chairman of the Board
Chief Financial Officer, Executive Vice President
Executive Vice President, People & Communication
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Denmark's Lundbeck <LUN.CO> has agreed to buy Alder BioPharmaceuticals <ALDR.O> in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.
Danish pharmaceutical company Lundbeck will acquire Alder BioPharmaceuticals in a deal valued at almost $2 billion, the company said in a statement on Monday.
Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.
* Posts quarterly operating profit below analyst expectations (Adds detail, background, more quotes and share price)
Danish drugmaker Lundbeck said on Tuesday it will lower dividends to shareholders as it seeks to invest more to make up for declining sales of older drugs.
Shares in Lundbeck fell 5 percent on Wednesday after third-quarter sales of the Danish drugmaker's new drugs disappointed and it had to rely on its old line up to prop up revenues.
Danish drug maker Lundbeck raised its full-year financial guidance on Wednesday citing "better-than-expected sales performance".
Shares in Lundbeck dropped as much as 10 percent on Wednesday after the Danish drugmaker failed to impress the market with revisions to its full-year profit outlook.
Danish drugmaker Lundbeck on Wednesday posted better than expected second quarter earnings and adjusted its full-year forecast to the upper end of the earlier guidance range.
Danish pharmaceutical company Lundbeck has picked Deborah Dunsire as its new chief executive after former CEO Kaare Schultz was poached by Teva last year.
Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.
Danish drugmaker Lundbeck said on Wednesday that it had reached a deal to pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.
* REG-FDA UPDATES TRINTELLIX® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD)
* INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS
Danish drugmaker Lundbeck posted weaker than expected fourth quarter operating profit and gave a broad range for its 2018 financial guidance because of a range of uncertainties.
Drugmaker Lundbeck's fourth-quarter operating profit came in at 932 million Danish crowns ($155.19 million), undershooting the 1.05 billion expected by analysts in a Reuters poll.
* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA
* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Acorda announces royalty monetization transactions for $53 million
Shares in Danish pharmaceutical firm Lundbeck fell as much as 6.8 percent on Tuesday as third-quarter sales of its newer drugs, such as those to treat bipolar disorder and depression, undershot market expectations.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.